zolmitriptan (zomig) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Zolmitriptan (Zomig; formerly 311C90) is a novel 5-hydroxytryptamine (5HT)1B/1D receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura. The N-desmethyl metabolite also has high affinity for 5-HT1B/1D and moderate affinity for 5-HT1A receptors. Migraines are likely due to local cranial vasodilatation and/or to the release of sensory neuropeptides (vasoactive intestinal peptide, substance P and calcitonin gene-related peptide) through nerve endings in the trigeminal system. The therapeutic activity of Zomig for the treatment of migraine headache is thought to be due to the agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system, which result in cranial vessel constriction, and inhibition of pro-inflammatory neuropeptide release.   NCATS

Chemistry

  • SMILES: CN(C)CCC1=CNC2=C1C=C(C[C@H]3COC(=O)N3)C=C2
  • InChIKey: ULSDMUVEXKOYBU-ZDUSSCGKSA-N
  • Mol. Mass: 287.3568
  • ALogP: 1.92
  • ChEMBL Molecule:
    zolmitriptan  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.9600 - $501.4100

Australia

$2.3026 - $2.8376
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

311c90 | 4-((3-(2-(dimethylamino)ethyl)-1h-indol-5-yl)methyl)-2-oxazolidinone | 4-[[3-(2-dimethylaminoethyl)-1h-indol-5-yl]methyl]oxazolidin-2-one | ascotop | astra brand of zolmitriptan | astrazeneca brand of zolmitriptan | ferrer brand of zolmitriptan | flezol | (s)-4-({3-[2-(dimethylamino)ethyl]-1h-indol-5-yl}methyl)-1,3-oxazolidin-2-one | zeneca brand of zolmitriptan | zipton | zolmitriptan | zolmitriptanum | zomig | zomigoro | zomig-zmt | zominat

Organizations (40)

Research & Development (17)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (24)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (4)


 

Cluster Headache

Migraine Disorders

Migraine with Aura (approved 1997)

Migraine without Aura (approved 1997)

Experimental Indications - Clinical Trial Phases 1-4 (4)


 

Cluster Headache (Phase 4)

Cocaine-Related Disorders (Early Phase 1)

Healthy Volunteers (Phase 1)

Migraine Disorders ()

Overview

  • Highest Phase: Phase 4
  • # of Trials: 20
  • # of Trial Organizations: 17

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue